Top View
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Chakiba Et Al NEJM 2018
- Touchoncology Touchexpert OPINIONS Acds in Solid
- We Seek to Improve Standards of Care in Cancer Treatment
- HER Family Receptor Activation and Dimerisation in Colorectal Cancer and Cancer-Derived Exosomes
- The Oncology Market for Antibody–Drug Conjugates
- Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer
- The Anti-HER3 Antibody Patritumab Abrogates Cetuximab Resistance Mediated by Heregulin in Colorectal Cancer Cells
- Targeted Therapy As a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: a Literature Review
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Daiichi Sankyo ESMO Follow-Up Meeting Hosted by Citi September 24, 2020 Forward-Looking Statements
- Press Release
- Therapeutic Advances in Oncology
- Antibody–Drug Conjugates in Solid Tumors: a Look Into Novel Targets Carmen Criscitiello1,2, Stefania Morganti1,2 and Giuseppe Curigliano1,2*
- Downloaded from the Cbio Portal (
- Supplementary Appendix
- Fe211a1d8a8bca4bff25c65c70ae
- (U3-1287) Process 2, a Fully Human Anti-HER3 Monoclonal Antibody in Combination with Erlotinib in Japanese Patients with Advanced Non-Small Cell Lung Cancer
- Novel Functional Anti-HER3 Monoclonal Antibodies with Potent Anti-Cancer Effects on Various Human Epithelial Cancers
- U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- Press Release
- 1 Patritumab with Cetuximab Plus Platinum-Containing Therapy In
- PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology
- Faculty Presentations)
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Imaging EGFR and HER3 Through 89Zr-Labeled MEHD7945A (Duligotuzumab) Received: 19 March 2018 Brooke N
- (INN) for Biological and Biotechnological Substances
- Of 2 the 43Rd Annual San Antonio Breast Cancer Symposium, SABCS
- Patritumab Or Placebo, with Cetuximab Plus Platinum Therapy in Recurrent Or Metastatic Squamous Cell Carcinoma of the Head and Neck: a Randomised Phase II Study
- Ep 3088005 A1
- And Bivalent Affibody-Based Fusion Proteins Targeting HER3 In
- Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Phase I Study of the HER3-Targeted Antibody Patritumab (U3-1287)
- Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1
- A Scdb-Based Trivalent Bispecific Antibody for T-Cell-Mediated Killing
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri